Orion publishes Half-Year Financial Report for January–June 2024 and holds a webcast on 8 August 2024
25 Luglio 2024 - 10:00AM
UK Regulatory
Orion publishes Half-Year Financial Report for January–June 2024
and holds a webcast on 8 August 2024
ORION CORPORATION
PRESS RELEASE
25 JULY 2024 at 11.00 EEST
Orion publishes Half-Year Financial Report for
January–June 2024 and holds a webcast on 8 August 2024
Orion will publish Half-Year Financial Report for January–June
2024 on Thursday, 8 August 2024 at approximately 12.00 noon EEST.
The report and related presentation material will be available on
the company’s website at www.orion.fi/en/investors after
publishing.
Webcast and conference call
A webcast and a conference call for analysts, investors and
media representatives will be held on Thursday, 8 August 2024 at
13.30 EEST.
A link to the live webcast is available on Orion's website
at www.orion.fi/en/investors. A recording of the event will be
available on the website later the same day.
Conference call can be joined by registering through the
following link:
https://palvelu.flik.fi/teleconference/?id=5007087
Phone numbers and the conference ID to access the conference
will be provided after the registration. In case you would like to
ask a question during the conference, please dial *5 on your
telephone keypad to enter the question queue.
Questions can also be presented in writing through the question
form of the webcast.
Silent period
The silent period preceding the publication is ongoing and
continues until the disclosure.
Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi
Orion is a globally operating Finnish pharmaceutical company – a
builder of well-being. We develop, manufacture and market human and
veterinary pharmaceuticals and active pharmaceutical ingredients.
Orion has an extensive portfolio of proprietary and generic
medicines and consumer health products. The core therapy areas of
our pharmaceutical R&D are oncology and pain. Proprietary
products developed by Orion are used to treat cancer, neurological
diseases and respiratory diseases, among others. Orion's net sales
in 2023 amounted to EUR 1,190 million and the company had about
3,600 employees at the end of the year. Orion's A and B shares are
listed on Nasdaq Helsinki.
Grafico Azioni Orion (BIT:1ORNBV)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Orion (BIT:1ORNBV)
Storico
Da Gen 2024 a Gen 2025
